Lexiva’s Updated Label Allows Concomitant PPI Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK/Vertex’s post-marketing study found that proton pump inhibitor use does not lessen the protease inhibitor’s efficacy.
You may also be interested in...
GSK Will Submit Data To FDA On Lexiva’s Comparability To Kaletra
Results of a GSK/Vertex head-to-head clinical study indicate that Lexiva plus ritonavir is comparable to Abbott’s Kaletra in treatment-naive HIV patients.
GSK Will Submit Data To FDA On Lexiva’s Comparability To Kaletra
Results of a GSK/Vertex head-to-head clinical study indicate that Lexiva plus ritonavir is comparable to Abbott’s Kaletra in treatment-naive HIV patients.
Reyataz Labeling Update Cautions Against Use With PPIs
Bristol-Myers Squibb’s protease inhibitor adds a study showing Prilosec substantially reduced plasma concentrations.